In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine

Psychopharmacology

Volumn 145, Issue 1, 1999, Pages 91-98

  Chang, Wen Ho ^a   Augustin, Bruce ^b   Lane, Hsien Yuan ^a   ZumBrunnen, Troy ^b   Liu, Hui Ching ^c   Kazmi, Yusuf ^a   Jann, Michael W ^b  

^a TAIPEI CITY PSYCHIATRIC CENTER   (Taiwan)

^b MERCER UNIVERSITY   (United States)

^c Hung Chi Psychiatric Hospital   (Taiwan)

Author keywords

Clozapine; CYP 450; Drug drug interaction; Fluvoxamine; In vitro; In vivo

Indexed keywords

CLOZAPINE; CLOZAPINE DERIVATIVE; CLOZAPINE N OXIDE; CYTOCHROME P450 INHIBITOR; ERYTHROMYCIN; FLUVOXAMINE; FURAFYLINE; NORCLOZAPINE; TROLEANDOMYCIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER MICROSOME; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA;

ADULT; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; CLOZAPINE; DRUG INTERACTIONS; FLUVOXAMINE; HUMANS; MALE; MICROSOMES, LIVER; MIDDLE AGED; SCHIZOPHRENIA;

EID: 0042485431     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130051036     Document Type: Article

References (52)

1. Armstrong SC, Stephans JR (1997) Blood clozapine levels elevated by fluvoxamine: Potential for side effects and lower clozapine dosage. J Clin Psychiatry 58:499
2. Bertilsson L, Cartillo JA, Dahl ML, Lierena A, Alm C, Bondesson U, Lindstrom L, Rodriguez de la Rubia S, Benitez J (1994) Clozapine disposition covaries with CYP 1A2 activity determined by a caffeine test. Br J Clin Pharmacol 38:471-473
3. Bertz RJ, Graanneman GR (1997) Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210 258
4. Brosen K, Skjelbo E, Rasmussen BB, Poulsen HE, Loft S (1993) Fluvoxamine is a potent inhibitor of cytochrome P 450 1A2. Biochem Pharmacol 45:1211-1214
5. Buchanan RW, Kirkpatrick B, Bryant N, Ball P, Brèier A (1996) Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 153:1625-1627
6. Catillo JA, Herraiz AG, Ramos SI, Benitez J (1998) Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol 18: 311-316
7. Centortino F, Baldessarni RJ, Kando J, Frankenberg FR, Volpicellii SA, Puopolo P, Flood JG (1994) Serum concentration of clozapine and its major metabolite: Effects of cotherapy with fluoxetine or valproate therapy. Am J Psychiatry 151:123 125
8. Centortino F, Baldessarni RJ, Frankenberg FR, Kando J, Volpicelli SA, Flood JG (1996) Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors. Am J Psychiatry 153:820-822
9. Chang WH, Lin SK, Lane HY, Hu WH, Jann MW, Lin HN (1997) Clozapine dosages and plasma drug concentrations. J Formos Med Assoc 96:599-605
10. Choc MG, Hsuan F, Honigfeld G, Robinson WT, Ereshefsky L, Ctismon ML, Saklad SR, Hirschowitz J, Wagner R (1990) Single vs multiple dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res 7:347-351
11. Chong SA, Tan CH, Lee HS (1997) Worsening of psychosis with clozapine and selective serotonin reuptake inhibitor combination: Two case reports. J Clin Psychopharmacol 17:68-69
12. Cohen LG, Chesley S, Eugenio L, Flood JG, Fisch J, Goff DC (1996) Erythromycin induced clozapine toxic reaction. Arch Int Med 156:675-677
13. Dain JG, Nicoletti J, Ballard F (1997) Biotransformation of clozapine in humans. Drug Metab Dispos 25:603-609
14. DeQuardo JR, Roberts M (1996) Elevated clozapine levels after fluvoxamine initiation. Am J Psychiatry 153:840-841
15. Edge SC, Markowitz JS. DeVane CL (1997) Clozapine drug drug interactions: A review of the literature. Hum Psychopharmacol 12:5-20
16. Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L (1997) The involvement of CYP 1A2 and CYP 3A4 in the metabolism of clozapine. Br J Clin Pharmacol 44:439-446
17. Fabrazzo M, Esposito G, Fusco R, Maj M (1996) Effect of treatment duration on plasma levels of clozapine and N-desmethylclozapine in men and women. Psychopharmacology 124:197-200
18. Fang J, Baker GB, Coutts RT, McKenna KF (1996) Elucidation of individual cytochrome P450 isoenzymes involved in the metabolism of clozapine. ISSX 7th North American Meeting 10:356
19. Freeman DJ, Oyewumi LK (1997) Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin Pharmacokinet 32:93-100
20. Funderberg LG, Vertress JE, True JE, Miller AL (1994) Seizure following addition of erythromycin to clozapine treatment. Am J Psychiatry 151:1840-1841
21. Haring C, Meise U, Humpel C, Saria A, Fleischbacker WW, Hinterhuber H (1989) Dose-related plasma levels of clozapine: Influence of smoking behavior, sex, and age. Psychopharmacology 99: S38-S40
22. Hiemke C, Weigmann H, Hartter S, Dahmen N, Wetzel H, Muller H (1994) Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 14:279-281
23. Jann MW, Grimsley SR, Gray EC, Chang WH (1993) Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 24:161-176
24. Jann MW, Liu HC, Wei FC, Lin SK, Hu WH, Chang WH (1997) Gender differences in plasma clozapine levels and its metabolites in schizophrenic patients. Hum Psychopharmacol 12:489-495
25. Jusko WT (1979) Influence of cigarette smoking on drug metabolism in man. Drug Metab Rev 9:221-236
26. Kane JM, Honigfeld G, Singer J, Meltzer HY, Clozaril Collaborative Study Group (1988) Clozapine for the treatment resistant schizophrenic: A double blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796
27. Koponen HJ, Leinonen E, Lepola U (1996) Fluvoxamine increases the clozapine serum levels significantly. Eur Neuropsychopharmacol 6:69-71
28. Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T, Kane JM, Lieberman JA (1995) Plasma clozapine levels and clinical response for treatment refractory schizophrenic patients. Am J Psychiatry 152:179-182
29. Kuo HJ, Lane HY, Chang WH (1998) Extrapyramidal symptoms following addition of fluvoxamine to clozapine. J Clin Psychopharmacol 18:483
30. Lane HY, Deng HC, Huang SM, Hu WH, Chang WH (1996) Low frequency of dextromethorphan O-demethylation deficiency in Chinese population. Clin Pharmacol Ther 60:696-698
31. Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW (1999) Effects of gender and age on the plasma levels of clozapine and its metabolites: Analyzed by critical statistics. J Clin Psychiatry 60:36-40
32. Lin SK, Chang WH, Chung MC, Lam YWF, Jann MW (1994) Disposition of clozapine and desmethylclozapine in schizophrenic patients. J Clin Pharmacol 34:318-324
33. Linnet K, Olesen OV (1997) Metabolism of clozapine by cDNA expressed human cytochrome P450 enzymes. Drug Metab Dispos 25:1379-1382
34. Liu HC, Chang WH, Wei FC, Lin SK, Lin SK, Jann MW (1996) Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther Drug Monitor 18:200-207
35. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacItyre A, Rance DJ, Wastall P (1997) The predication of human pharmacokinetic parameters from preclinical and in-vitro metabolism data. J Pharmacol Exp Ther 283:46-58
36. Olesen OV (1998) Therapeutic drug monitoring of clozapine treatment. Clin Pharmacokinet 34:497-502
37. Omurea T, Saot R (1964) The carbon-monooxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378
38. Perry PJ, Miller DD, Arndt SV, Cadoret RJ (1991) Clozapine and norclozapine plasma concentrations and clinical response of treatment refractory schizophrenic patients. Am J Psychiatry 148: 231-235
39. Pirmohamed M, Williams D, Madden S, Templeton E, Park BK (1995) Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 272:984-990
40. Shader RI, Greenblatt DJ (1998) Clozapine and fluvoxamine. Acurious complexity. J Clin Psychopharmacol 18:101-102
41. Schmider J, Greenblatt DJ, vonMoltke LL, Shader RI (1996) Relationship of in vitro on drug metabolism to in vivo pharmacokinetics and drug interactions: Implications for diazepam disposition in humans. J Clin Psychopharmacol 16:267-272
42. Szegedi A, Wiesner J, Hiemke C (1995) Improved efficacy and fewer side effects under clozapine treatment after addition of fluvoxamine. J Clin Psychopharmacol 15:141-142
43. Taylor D (1997) Pharmacokinetic interactions involving clozapine. Br J Psychiatry 171:109-112
44. Taylor D, Ellison Z, Shaw LE, Wickman H, Murray R (1998) Co-administration of citalopram and clozapine: Effect on plasma clozapine levels. Int Clin Psychopharmacol 13:19-21
45. Tugnait M, Hawes EM, McKay G, Rettie AE, Haining RL, Midha KK (1997) N-Oxygenation of clozapine by flavin containing monooxygenase. Drug Metab Dispos 25:524-527
46. VanderZwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson W, Cooper TB (1996) Response of patients with treatment refractory schizophrenia to clozapine with three serum level ranges. Am J Psychiatry 153:1579-1584
47. Van Harten J (1995) Overview of the pharmacokinetics of fluvoxamine. Clin Pharmacokinet 29:1-9
48. von Moltke L, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI (1995) Metabolism of drugs by cytochrome P450 3A4 isoforms. Clin Pharmacokinet 29:33-44
49. Wagstaff AJ, Bryson HM (1995) Clozapine. CNS Drugs 4:370-400
50. Weigmann H, Muller H, Dahmen N, Wetzel H, Hiemke C (1993) Interactions of fluvoxamine with the metabolism of clozapine. Pharmacopsychiatry 26:209
51. Wetzel H, Anghelesch I, Szegedi A, Wiesner J, Weigmann H, Harter S, Hiemke C (1998) Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: Differential effects of fluvoxamine and paroxetine in a prospective study. J Clin Psychopharmacol 18:2-9
52. Xu ZH, Xie HG, Zhou HH (1996) In vivo inhibition of CYP 2C19 but not CYP 2D6 by fluvoxamine. Br J Clin Pharmacol 42:518-521